DBV Technologies | DBVT - Ordinary Share Capital


DBV Technologies reported $235.6M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 171.09M 1.9M Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amarin USD 20.81M 13K Dec/2025
BioCryst Pharmaceuticals USD 255.26M 42.2M Jun/2026
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
DBV Technologies USD 235.6M 98.78M Dec/2025
Galectin Therapeutics USD 61K 0 Dec/2023
Halozyme Therapeutics USD 114.04M 4.48M Jun/2026
Incyte USD 200.98M 1.03M Jun/2026
Insmed USD 218.28M 1.76M Jun/2026
Ionis Pharmaceuticals USD 165.64M 265K Jun/2026
Neurocrine Biosciences USD 100.55M 50K Jun/2026
PTC Therapeutics USD 83.33M 445K Jun/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
United Therapeutics USD 42.68M 521K Jun/2026